EU agency backs new use of Bayer's drug Zevalin

LONDON, March 20 (Reuters) - The European Medicines Agency said on Thursday it had recommended approval of Bayer's BAYG.DE cancer drug Zevalin in treating follicular lymphoma.

The medicine is currently authorised for patients with follicular B-cell non-Hodgkin's lymphoma, in combination with rituximab.

Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months. (Reporting by Ben Hirschler)